Provectus Biopharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 29, 2022 and accepted by EDGAR at Mar 29, 2022, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2021-01-01 to 2021-12-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $961.7k | us-gaap:InterestExpense |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$5.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$1.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | $683.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $3.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $3.5m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $7.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $7.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | −$4.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-008016. Last ingested by Listed: Oct 30, 2026, 11:33 ET. Listed shows no prices and gives no investment advice.